Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal incidences of bronchopulmonary dysplasia(BPD) and/or death. But not all preterm infants with RDS can be beneficial. Otherwise, the international neonatal acute RDS (NARDS) collaborative group provides the first consensus definition for NARDS in 2017. And whether or not PS being beneficial in preterm infants with NARDS remains unknown.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• Collaborator: Children's Hospital of Chongqing Medical University

Criteria

Inclusion Criteria:

• gestation age less than or equal to 32 weeks

• PS is needed

Exclusion Criteria:

• main congenital abnormalities

• parents' refusal or quit